Compare Dishman Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs NATCO PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA NATCO PHARMA DISHMAN PHARMA/
NATCO PHARMA
 
P/E (TTM) x 25.1 35.8 70.2% View Chart
P/BV x 3.3 5.1 65.8% View Chart
Dividend Yield % 0.7 0.7 100.1%  

Financials

 DISHMAN PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
NATCO PHARMA
Mar-19
DISHMAN PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs374849 44.1%   
Low Rs129557 23.1%   
Sales per share (Unadj.) Rs197.8573.8 34.5%  
Earnings per share (Unadj.) Rs21.2176.0 12.0%  
Cash flow per share (Unadj.) Rs34.7198.2 17.5%  
Dividends per share (Unadj.) Rs2.006.25 32.0%  
Dividend yield (eoy) %0.80.9 89.4%  
Book value per share (Unadj.) Rs179.9842.7 21.3%  
Shares outstanding (eoy) m80.6936.50 221.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.31.2 103.8%   
Avg P/E ratio x11.94.0 297.1%  
P/CF ratio (eoy) x7.23.5 204.3%  
Price / Book Value ratio x1.40.8 167.7%  
Dividend payout %9.43.6 265.6%   
Avg Mkt Cap Rs m20,30625,660 79.1%   
No. of employees `0000.85.0 16.7%   
Total wages/salary Rs m5,3553,559 150.5%   
Avg. sales/employee Rs Th19,252.74,225.3 455.6%   
Avg. wages/employee Rs Th6,459.5718.0 899.7%   
Avg. net profit/employee Rs Th2,064.11,295.9 159.3%   
INCOME DATA
Net Sales Rs m15,96120,945 76.2%  
Other income Rs m2651,302 20.4%   
Total revenues Rs m16,22622,247 72.9%   
Gross profit Rs m4,1037,948 51.6%  
Depreciation Rs m1,091810 134.6%   
Interest Rs m944193 489.3%   
Profit before tax Rs m2,3348,247 28.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,823 34.2%   
Profit after tax Rs m1,7116,424 26.6%  
Gross profit margin %25.737.9 67.7%  
Effective tax rate %26.722.1 120.9%   
Net profit margin %10.730.7 35.0%  
BALANCE SHEET DATA
Current assets Rs m11,01823,472 46.9%   
Current liabilities Rs m9,5177,287 130.6%   
Net working cap to sales %9.477.3 12.2%  
Current ratio x1.23.2 35.9%  
Inventory Days Days11092 119.8%  
Debtors Days Days3588 39.5%  
Net fixed assets Rs m16,30418,648 87.4%   
Share capital Rs m161365 44.2%   
"Free" reserves Rs m12,90734,525 37.4%   
Net worth Rs m14,51630,760 47.2%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80543,031 69.3%  
Interest coverage x3.543.7 7.9%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.5 110.0%   
Return on assets %8.915.4 57.9%  
Return on equity %11.820.9 56.4%  
Return on capital %17.527.4 63.9%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95211,536 42.9%   
Fx outflow Rs m6972,939 23.7%   
Net fx Rs m4,2558,597 49.5%   
CASH FLOW
From Operations Rs m2,7866,688 41.7%  
From Investments Rs m-1,529-6,122 25.0%  
From Financial Activity Rs m-941-509 184.9%  
Net Cashflow Rs m31666 479.4%  

Share Holding

Indian Promoters % 61.4 52.0 118.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 3.7 7.8 47.2%  
FIIs % 12.7 16.6 76.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 26.0 85.0%  
Shareholders   46,261 25,395 182.2%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  ABBOTT INDIA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS